Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $10.00 price target on the stock.

Other equities research analysts also recently issued research reports about the company. UBS Group cut their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company reduced their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Finally, Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $1.79 on Thursday. Zentalis Pharmaceuticals has a 52-week low of $1.61 and a 52-week high of $16.27. The firm has a market cap of $127.56 million, a price-to-earnings ratio of -0.72 and a beta of 1.75. The business’s fifty day moving average is $2.05 and its 200-day moving average is $2.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter. As a group, research analysts forecast that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, Director Jan Skvarka bought 60,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the acquisition, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Ingmar Bruns purchased 20,000 shares of the business’s stock in a transaction on Thursday, February 6th. The shares were purchased at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. The trade was a 120.27 % increase in their position. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ZNTL. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Zentalis Pharmaceuticals by 126.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock worth $843,000 after acquiring an additional 127,868 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $75,000. Martingale Asset Management L P bought a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $91,000. Capstone Investment Advisors LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at about $48,000. Finally, Verition Fund Management LLC increased its position in Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after buying an additional 951,500 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.